Generation Bio and Vir Biotechnology have agreed to collaborate on research into the use of monoclonal antibodies against the SARS-CoV-2 virus that causes COVID-19.
Johnson & Johnson has selected a lead COVID-19 vaccine candidate from a number of options it has been working on since January. The company hopes to release a vaccine by 2021.
Charles River Laboratories has entered into a partnership with software firm Deciphex to offer a digital pathology workflow platform.
LabShares Newton is offering free, fully equipped biosafety level 2 lab space, facilities, and resources for researchers addressing the global COVID-19 pandemic, it announced on March 30.
Medical simulation software company Simulations Plus announced that it has created a program to speed up consulting assistance to scientists working on COVID-19 research.
Atum has granted commercial and academic laboratories free access to its Leap-In Transposase protein production platform for use in creating tools and resources to battle the COVID-19 pandemic.
Biopharmaceutical companies Xencor and Vir Biotechnology have entered into a technology licensing agreement to develop potential antibody-based treatments for patients with COVID-19.
Vycellix and Avectas have unveiled plans to collaborate on the development of cell-based immunotherapeutic products.
New survey results suggest that clinical trials are experiencing significant roadblocks associated with COVID-19. These could ultimately result in a slowdown of global drug development, according to Clinical Research IO.
Twist Bioscience's synthetic SARS-CoV-2 RNA quality controls for the development, verification, and validation of diagnostic tests for SARS-CoV-2 are now included in the U.S. Food and Drug Administration's (FDA) reference materials.